1. American College of Rheumatology Ad Hoc Com mittee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. Arthritis Rheum 2002; 47(4):429–433. doi:10.1002/art.10381
2. Rang M. The Ulysses syndrome. Can Med Assoc J 1972; 106(2):122–123. pmid:5058884
3. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers 2013; 35(6):727–734. doi:10.1155/2013/726598
4. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146(11):797–808. pmid:17548411
5. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011; 2011:815038. doi:10.4061/2011/815038
6. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48(10):2741–2749. doi:10.1002/art.11223
7. Suresh E. Diagnosis of early rheumatoid arthritis: what the nonspecialist needs to know. J R Soc Med 2004; 97(9):421–424. doi:10.1258/jrsm.97.9.421
8. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61(4):290–297. pmid:11874828
9. Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76(6):948–959. doi:10.1136/annrheumdis-2016-210602
10. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. J Rheumatol 1995; 22(12):2208–2213. pmid:8835550
11. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124(8):699–707. pmid:8633829
12. Andreson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43(1):22–29. doi:10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9
13. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9):2569–2581. doi:10.1002/art.27584
14. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specifi c autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50(2):380–386. doi:10.1002/art.20018
15. del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988; 31(10):1239–1244. pmid:3178905
16. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am 2010; 36(2):213–241. doi:10.1016/j.rdc.2010.02.001
17. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specifi c autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000; 124(1):71–81. doi:10.1043/0003-9985(2000)124<0071:GFCUOT>2.0.CO;2
18. Suresh E. Systemic lupus erythematosus: diagnosis for the nonspecialist. Br J Hosp Med (Lond) 2007; 68(10):538–541. doi:10.12968/hmed.2007.68.10.27324
19. Illei GG, Klippel JH. Why is the ANA result positive? Bull Rheum Dis 1999; 48(1):1–4. pmid:10028188
20. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997; 40(9):1601–1611. doi:10.1002/1529-0131(199709)40:9<1601::AID-ART9>3.0.CO;2-T
21. Langkilde H, Voss A, Heegaard N, Laustrup H. Autoantibodies persist in relatives to systemic lupus erythematosus patients during 12 years follow-up. Lupus 2017; 26(7):723–728. doi:10.1177/0961203316676378
22. Rondeel JM. Immunofluorescence versus ELISA for the detection of antinuclear antigens. Expert Rev Mol Diagn 2002; 2(3):226–232. doi:10.1586/14737159.2.3.226
23. Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002; 47(4):434–444. doi:10.1002/art.10561
24. Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. A study of clinical utility. Arch Intern Med 1996; 156(13):1421–1425. pmid:8678710
25. Maddison PJ. Is it SLE? Best Pract Res Clin Rheumatol 2002; 16(2):167–180. doi:10.1053/berh.2001.0219
26. Price E, Walker E. Diagnostic vertigo: the journey to diagnosis in systemic lupus erythematosus. Health (London) 2014; 18(3):223–239. doi:10.1177/1363459313488008
27. Blumenthal DE. Tired, aching, ANA-positive: does your patient have lupus or fibromialgia? Cleve Clin J Med 2002; 69(2):143–146, 151–152. pmid:11990644
28. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classifi cation criteria for defi nite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2):295–306. doi:10.1111/j.1538-7836.2006.01753.x
29. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157(1):47–58. doi:10.1111/j.1365-2141.2012.09037.x
30. Giannakopoulos B, Passam F, Iannou Y, Krillis SA. How we diagnose the antiphospholipid syndrome. Blood 2009; 113(5):985–994. doi:10.1182/blood-2007-12-129627
31. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010; 9(5):A299–A304. doi:10.1016/j.autrev.2009.11.013
32. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profi le: a multicenter prospective study. Blood 2011; 118(17):4714–4718. doi:10.1182/blood-2011-03-340232
33. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8(2):237–242. doi:10.1111/j.1538-7836.2009.03674.x
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.